Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- yes (7)
Document Type
- Journal article (7)
Language
- English (7) (remove)
Keywords
- kinematics (2)
- 5IA-SPECT (1)
- Cell therapy (1)
- EEG data (1)
- L-DOPA (1)
- Mesenchymal stem/stromal cells (1)
- Parkinson disease (1)
- Parkinson's disease (1)
- Parkinson’s disease (1)
- Progressive supranuclear palsy (1)
- Regenerative medicine (1)
- Richardson-Olszewski-Syndrome (1)
- activation (1)
- adrenal medulla (1)
- advanced therapy medicinal products (1)
- ankles (1)
- biological locomotion (1)
- bone-marrow (1)
- bradykinesia (1)
- brain dynamics (1)
- cellular therapy (1)
- children (1)
- cognitive decline (1)
- coherence (1)
- cortical oscillatory activity (1)
- deep brain-stimulation (1)
- dopamine acetylcholine (1)
- event-related desynchronization (1)
- gait analysis (1)
- gait modulation (1)
- locus coeruleus (1)
- mesenchymal stem and stromal cells (1)
- multiple system atrophy (1)
- nicotinic receptors (1)
- noradrenaline (1)
- obstacle avoidance (1)
- progressive supranuclear palsy (1)
- reaction-time tasks (1)
- receptor tyrosine kinase (1)
- reserpinized rat model (1)
- rett (1)
- soleus muscles (1)
- stromal cells (1)
- syndrome (1)
- transplantation (1)
- treatment options (1)
- tremor (1)
- velocity (1)
- virtual reality (1)
- voluntary movement (1)
- walking (1)
The pathophysiology of tremor in Parkinson’s disease (PD) is evolving towards a complex alteration to monoaminergic innervation, and increasing evidence suggests a key role of the locus coeruleus noradrenergic system (LC-NA). However, the difficulties in imaging LC-NA in patients challenge its direct investigation. To this end, we studied the development of tremor in a reserpinized rat model of PD, with or without a selective lesioning of LC-NA innervation with the neurotoxin DSP-4. Eight male rats (Sprague Dawley) received DSP-4 (50 mg/kg) two weeks prior to reserpine injection (10 mg/kg) (DR-group), while seven male animals received only reserpine treatment (R-group). Tremor, rigidity, hypokinesia, postural flexion and postural immobility were scored before and after 20, 40, 60, 80, 120 and 180 min of reserpine injection. Tremor was assessed visually and with accelerometers. The injection of DSP-4 induced a severe reduction in LC-NA terminal axons (DR-group: 0.024 ± 0.01 vs. R-group: 0.27 ± 0.04 axons/um\(^2\), p < 0.001) and was associated with significantly less tremor, as compared to the R-group (peak tremor score, DR-group: 0.5 ± 0.8 vs. R-group: 1.6 ± 0.5; p < 0.01). Kinematic measurement confirmed the clinical data (tremor consistency (% of tremor during 180 s recording), DR-group: 37.9 ± 35.8 vs. R-group: 69.3 ± 29.6; p < 0.05). Akinetic–rigid symptoms did not differ between the DR- and R-groups. Our results provide preliminary causal evidence for a critical role of LC-NA innervation in the development of PD tremor and foster the development of targeted therapies for PD patients.